Amgen Explains How Big A Hit It May Take From Biosimilars, Pricing Pressures
Executive Summary
With Neulasta and Epogen facing competition and potential Sensipar generics launching this year, the company said revenues will fall from $23.7bn in 2018 to $21.8bn-$22.9bn in 2019. Amgen expects new launches and volume-driven sales growth – not price hikes – to boost revenue in the future.
You may also be interested in...
After Two Jury Verdicts, Court Finds Repatha Patents Invalid
Delaware district court rules patent claims for antibodies targeting PCSK9 are invalid for lack of enablement; saga to continue with Amgen appeal.
After Two Jury Verdicts, Court Finds Repatha Patents Invalid
Delaware district court rules patent claims for antibodies targeting PCSK9 are invalid for lack of enablement; saga to continue with Amgen appeal.
Amgen's $13.4bn Otezla Buy Helps Bristol/Celgene Merger Close By Year-End
Amgen sees opportunity to grow Otezla sales through new indications and additional ex-US launches. The deal depends on Bristol closing its Celgene acquisition, pending FTC clearance.